There is a saying, popular amongst paediatricians, that 'children are not small adults' and perhaps this issue of the *Journal of Virus Eradication* illustrates the complexities of acquiring HIV-1 infection perinatally on an immature immune system. Reviews by Gianesen *et al*. and Cotugno *et al*. highlight the differences between perinatal and adult HIV-1 infection. Infants have a very small pool of circulating central memory CD4+ T lymphocytes and very early antiretroviral therapy (ART) restricts the size of the latent viral reservoir. The potential impact of early treatment in achieving steps towards a 'functional cure' and the hurdles faced are further explored by Martinez-Bonet *et al*. The EPIICAL project sets out an exciting global paediatric collaboration with the development of a comprehensive research platform to fast track cure research strategies within this unique early treated cohort.

However, the sobering fact remains that despite the huge global gains made in prevention of mother to child transmission (PMTCT), almost a quarter of a million children are infected annually. The vast majority of these children will not be diagnosed or start ART in the first weeks of life and they continue to face a life-time on treatment, with the associated long-term toxicities of exposure both to HIV and ART throughout postnatal growth and development increasingly apparent.

The PENTA collaboration (Paediatric European Network for Treatment of AIDS; www.penta-id.org), originally established in 1991, and currently encompassing more than 80 clinical centres in 18 countries undertakes independent clinical trials to address questions about antiretroviral therapy in HIV infected children where answers cannot be extrapolated from trials in adults. Activities also include cohort studies, collaboration (EPPICC), pregnancy studies (including PhaseI trials in pregnant women) and training/educational programmes both on HIV and in non-HIV areas. In 2011, PENTA expanded into PENTA-*ID*, highlighting the role for co-ordinated research networks in other areas of paediatric infectious diseases, particularly where therapies for children continue to lag behind those available for their parents. The call for timely equity of access to treatment is eloquently argued for the case of HCV by Thorne and colleagues. However, it is the devastating personal account of Tejshri Shah, a paediatrican working in Sierra Leone, that focuses the mind on the importance of global collaboration at every level of society in tackling infectious diseases, the burden of which falls disproportionately on the young.
